clinical trial · NCT05743881
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
ModernaTX, Inc.·phase1·active not recruiting·n = 186
Respiratory Syncytial VirusHuman MetapneumovirusmRNA-1345mRNA-1365PlaceboNimenrix
brief summary
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.
started
Feb 15, 2023
primary completion
Aug 31, 2026
completion
Sep 30, 2026
last updated
Nov 24, 2025
official title
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol